EE200000778A - 4-bensüülpiperidiinalküülsulfoksiidi heterotsüklid ja nende kasutamine NMDA retseptori alaliikide suhtes selektiivsete antagonistidena - Google Patents

4-bensüülpiperidiinalküülsulfoksiidi heterotsüklid ja nende kasutamine NMDA retseptori alaliikide suhtes selektiivsete antagonistidena

Info

Publication number
EE200000778A
EE200000778A EEP200000778A EEP200000778A EE200000778A EE 200000778 A EE200000778 A EE 200000778A EE P200000778 A EEP200000778 A EE P200000778A EE P200000778 A EEP200000778 A EE P200000778A EE 200000778 A EE200000778 A EE 200000778A
Authority
EE
Estonia
Prior art keywords
benzylpiperidinealkylsulfoxide
heterocycles
nmda receptor
receptor subtypes
selective antagonists
Prior art date
Application number
EEP200000778A
Other languages
English (en)
Estonian (et)
Inventor
L. Wright Jonathan
Ross Kesten Suzanne
B. Upasani Ravindra
C. Lan Nancy
Original Assignee
Warner-Lambert Company
Cocensys, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Warner-Lambert Company, Cocensys, Inc. filed Critical Warner-Lambert Company
Publication of EE200000778A publication Critical patent/EE200000778A/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Pain & Pain Management (AREA)
  • Ophthalmology & Optometry (AREA)
  • Cardiology (AREA)
  • Psychiatry (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Epidemiology (AREA)
  • Urology & Nephrology (AREA)
  • Pulmonology (AREA)
  • Vascular Medicine (AREA)
  • Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
EEP200000778A 1998-06-26 1999-06-25 4-bensüülpiperidiinalküülsulfoksiidi heterotsüklid ja nende kasutamine NMDA retseptori alaliikide suhtes selektiivsete antagonistidena EE200000778A (et)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US9091498P 1998-06-26 1998-06-26
PCT/US1999/014291 WO2000000197A1 (en) 1998-06-26 1999-06-25 4-benzyl piperidine alkylsulfoxide heterocycles and their use as subtype-selective nmda receptor antagonists

Publications (1)

Publication Number Publication Date
EE200000778A true EE200000778A (et) 2002-04-15

Family

ID=22224939

Family Applications (1)

Application Number Title Priority Date Filing Date
EEP200000778A EE200000778A (et) 1998-06-26 1999-06-25 4-bensüülpiperidiinalküülsulfoksiidi heterotsüklid ja nende kasutamine NMDA retseptori alaliikide suhtes selektiivsete antagonistidena

Country Status (28)

Country Link
US (1) US6284774B1 (ja)
EP (1) EP1089735B1 (ja)
JP (1) JP2002519322A (ja)
KR (1) KR20010053170A (ja)
CN (1) CN1304307A (ja)
AP (1) AP2000001949A0 (ja)
AT (1) ATE297207T1 (ja)
AU (1) AU769650B2 (ja)
BG (1) BG105082A (ja)
BR (1) BR9911575A (ja)
CA (1) CA2327888A1 (ja)
DE (1) DE69925730T2 (ja)
EA (1) EA200100058A1 (ja)
EE (1) EE200000778A (ja)
ES (1) ES2244201T3 (ja)
HU (1) HUP0102471A2 (ja)
ID (1) ID28005A (ja)
IL (1) IL138949A0 (ja)
IS (1) IS5667A (ja)
NO (1) NO20006482L (ja)
NZ (1) NZ508808A (ja)
OA (1) OA11570A (ja)
PE (1) PE20000728A1 (ja)
PL (1) PL345024A1 (ja)
SK (1) SK19512000A3 (ja)
TR (1) TR200003888T2 (ja)
WO (1) WO2000000197A1 (ja)
ZA (1) ZA200005848B (ja)

Families Citing this family (55)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6476041B1 (en) 1999-10-29 2002-11-05 Merck & Co., Inc. 1,4 substituted piperidinyl NMDA/NR2B antagonists
UA73749C2 (en) * 1999-11-01 2005-09-15 Diarylenines
CZ20023479A3 (cs) 2000-04-26 2003-04-16 Warner-Lambert Company Cyklohexylaminový derivát, jako subtyp selektivních antagonistů NMDA receptoru
JP2003535073A (ja) * 2000-06-01 2003-11-25 ワーナー−ランバート・カンパニー、リミテッド、ライアビリティ、カンパニー サブタイプ選択性ｎｍｄａレセプター拮抗物質としてのシクロヘキシルアミン誘導体
WO2002006231A1 (fr) * 2000-07-18 2002-01-24 Sumitomo Pharmaceuticals Co., Ltd. Inhibiteurs de recaptage de la serotonine
IL145584A0 (en) 2000-10-02 2002-06-30 Pfizer Prod Inc Nmda nr2b antagonists for treatment
HU227197B1 (en) 2000-10-24 2010-10-28 Richter Gedeon Nyrt Nmda receptor antagonist carboxylic acid amide derivatives and pharmaceutical compositions containing them
EP1379520B2 (en) 2001-02-23 2014-04-09 Merck Sharp & Dohme Corp. N-substituted nonaryl-heterocyclic nmda/nr2b antagonists
AU2002250256B2 (en) * 2001-03-08 2008-04-03 Emory University pH-dependent NMDA receptor antagonists
CA2443108A1 (en) 2001-04-03 2002-10-17 Merck & Co. Inc. N-substituted nonaryl-heterocyclo amidyl nmda/nr2b antagonists
CA2381630A1 (en) * 2001-04-23 2002-10-23 Leonard Theodore Meltzer Method for preventing dyskinesias
ATE408611T1 (de) 2001-07-24 2008-10-15 Richter Gedeon Nyrt Piperidine als nmda-rezeptorantagonisten
WO2003020702A2 (en) 2001-08-31 2003-03-13 The Rockefeller University Phosphodiesterase activity and regulation of phosphodiesterase 1-b-mediated signaling in brain
US20060281797A1 (en) * 2001-12-11 2006-12-14 University Of Virginia Patent Foundation Neurorestoration with R(+) Pramipexole
IL162408A0 (en) * 2001-12-11 2005-11-20 Univ Virginia Use of pramipexole to treat amyotrophic lateral scelrosis
US20040082543A1 (en) * 2002-10-29 2004-04-29 Pharmacia Corporation Compositions of cyclooxygenase-2 selective inhibitors and NMDA receptor antagonists for the treatment or prevention of neuropathic pain
US7732162B2 (en) 2003-05-05 2010-06-08 Probiodrug Ag Inhibitors of glutaminyl cyclase for treating neurodegenerative diseases
US8389578B2 (en) 2004-11-24 2013-03-05 Adamas Pharmaceuticals, Inc Composition and method for treating neurological disease
JP2008525439A (ja) * 2004-12-23 2008-07-17 ボイジャー・ファーマシューティカル・コーポレーション アルツハイマー病の治療のための酢酸ロイプロリド及びアセチルコリンエステラーゼインヒビターまたはｎｍｄａレセプターアゴニスト
CA2619217A1 (en) * 2005-08-15 2007-02-22 University Of Virginia Patent Foundation Neurorestoration with r(+) pramipexole
US8518926B2 (en) 2006-04-10 2013-08-27 Knopp Neurosciences, Inc. Compositions and methods of using (R)-pramipexole
WO2007137071A2 (en) 2006-05-16 2007-11-29 Knopp Neurosciences, Inc. Compositions of r(+) and s(-) pramipexole and methods of using the same
EP2089383B1 (en) 2006-11-09 2015-09-16 Probiodrug AG 3-hydr0xy-1,5-dihydr0-pyrr0l-2-one derivatives as inhibitors of glutaminyl cyclase for the treatment of ulcer, cancer and other diseases
US9126987B2 (en) 2006-11-30 2015-09-08 Probiodrug Ag Inhibitors of glutaminyl cyclase
US8524695B2 (en) 2006-12-14 2013-09-03 Knopp Neurosciences, Inc. Modified release formulations of (6R)-4,5,6,7-tetrahydro-N6-propyl-2,6-benzothiazole-diamine and methods of using the same
AU2008220785B2 (en) 2007-03-01 2013-02-21 Vivoryon Therapeutics N.V. New use of glutaminyl cyclase inhibitors
AU2008224844B2 (en) 2007-03-14 2012-08-09 Knopp Neurosciences, Inc. Synthesis of chirally purified substituted benzothiazole diamines
US9656991B2 (en) 2007-04-18 2017-05-23 Probiodrug Ag Inhibitors of glutaminyl cyclase
US8420680B2 (en) 2007-06-29 2013-04-16 Emory University NMDA receptor antagonists for neuroprotection
DE102007047737A1 (de) * 2007-10-05 2009-04-30 Merck Patent Gmbh Piperidin- und Piperazinderivate
TWI410420B (zh) 2008-02-05 2013-10-01 Dainippon Sumitomo Pharma Co 苄基哌啶化合物
CA2721360A1 (en) 2008-04-18 2009-10-22 Arizona Board Of Regents, A Body Corp. Of The State Of Arizona, Acting F Or And On Behalf Of The University Of Arizona Methods and compositions for treating and identifying compounds to treat age-related macular degeneration
CA2734491A1 (en) 2008-08-19 2010-02-25 Knopp Neurosciences, Inc. Compositions and methods of using (r)-pramipexole
HUP0900130A3 (en) 2009-03-03 2012-02-28 Richter Gedeon Nyrt Novel crystalline hydrate, amorphous and polymorphic forms of dihydro-benzoxazole-6-yl-acetamide derivative and processes for their preparation
US8778970B2 (en) 2009-08-04 2014-07-15 Dainippon Sumitomo Pharma Co., Ltd Benzyl piperidine compound
WO2011016861A2 (en) 2009-08-05 2011-02-10 Intra-Cellular Therapies, Inc. Novel regulatory proteins and inhibitors
PL2475428T3 (pl) 2009-09-11 2015-12-31 Probiodrug Ag Pochodne heterocykliczne jako inhibitory cyklazy glutaminowej
CA2782556C (en) 2009-12-02 2018-03-27 Adamas Pharmaceuticals, Inc. Amantadine compositions and methods of use
US9181233B2 (en) 2010-03-03 2015-11-10 Probiodrug Ag Inhibitors of glutaminyl cyclase
DK2545047T3 (da) 2010-03-10 2014-07-28 Probiodrug Ag Heterocycliske inhibitorer af glutaminylcyclase (QC, EC 2.3.2.5)
WO2011131748A2 (en) 2010-04-21 2011-10-27 Probiodrug Ag Novel inhibitors
EP2686313B1 (en) 2011-03-16 2016-02-03 Probiodrug AG Benzimidazole derivatives as inhibitors of glutaminyl cyclase
SG11201402472QA (en) 2011-11-22 2014-06-27 Univ California Cysteamine and/or cystamine for treating ischemic injury
WO2013096816A1 (en) 2011-12-22 2013-06-27 Biogen Idec Ma Inc. Improved synthesis of amine substituted 4,5,6,7-tetrahydrobenzothiazole compounds
US9662313B2 (en) 2013-02-28 2017-05-30 Knopp Biosciences Llc Compositions and methods for treating amyotrophic lateral sclerosis in responders
WO2014204933A1 (en) 2013-06-17 2014-12-24 Adamas Pharmaceuticals, Inc. Amantadine compositions and methods of use
US9468630B2 (en) 2013-07-12 2016-10-18 Knopp Biosciences Llc Compositions and methods for treating conditions related to increased eosinophils
DK3019167T3 (da) 2013-07-12 2021-03-15 Knopp Biosciences Llc Behandling af forhøjede niveauer af eosinophiler og/eller basophiler
EP3033081B1 (en) 2013-08-13 2021-05-12 Knopp Biosciences LLC Compositions and methods for treating chronic urticaria
WO2015023786A1 (en) 2013-08-13 2015-02-19 Knopp Biosciences Llc Compositions and methods for treating plasma cell disorders and b-cell prolymphocytic disorders
US10633336B2 (en) 2014-12-19 2020-04-28 The Broad Institute, Inc. Dopamine D2 receptor ligands
EP3233799B1 (en) 2014-12-19 2021-05-19 The Broad Institute, Inc. Dopamine d2 receptor ligands
IL272834B1 (en) 2017-08-24 2024-04-01 Adamas Pharma Llc Compositions of amantadine, their preparation, and methods of use
PL3461819T3 (pl) 2017-09-29 2020-11-30 Probiodrug Ag Inhibitory cyklazy glutaminylowej
EP3958973A4 (en) * 2019-04-26 2023-06-07 Cytosolve, Inc. COMPOSITIONS TO IMPROVE BRAIN HEALTH AND MEMORY

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BE792187A (fr) * 1971-12-03 1973-03-30 Sumitomo Chemical Co Nouveaux derives d'alkylamines
DE2845537A1 (de) 1978-10-19 1980-04-30 Bayer Ag Benzimidazolylcarbamidsaeureester, verfahren zu ihrer herstellung sowie ihre verwendung als arzneimittel
ZA848275B (en) * 1983-12-28 1985-08-28 Degussa New piridine-2-ethers or pyridine-2-thioethers having a nitrogen-containing cycloaliphatic ring
EP0488959A3 (en) 1990-11-28 1992-08-05 Sandoz Ltd. New uses of competitive nmda receptor antagonists
JPH05194505A (ja) * 1991-08-09 1993-08-03 Yoshitomi Pharmaceut Ind Ltd チオフェン化合物
US5192751A (en) 1992-07-24 1993-03-09 Eli Lilly And Company Use of competitive NMDA receptor antagonists in the treatment of urinary incontinence
JP2959615B2 (ja) * 1993-06-24 1999-10-06 吉富製薬株式会社 縮合型チオフェン化合物およびその医薬用途
ATE174915T1 (de) 1994-10-31 1999-01-15 Merck Patent Gmbh Benzylpiperidinderivate mit hoher affinität zu bindungsstellen von aminosäure-rezeptoren
AU5271296A (en) * 1995-04-07 1996-10-23 Novo Nordisk A/S Novel method
ZA9610745B (en) * 1995-12-22 1997-06-24 Warner Lambert Co 4-Subsituted piperidine analogs and their use as subtype selective nmda receptor antagonists
ZA9610741B (en) * 1995-12-22 1997-06-24 Warner Lambert Co 4-Substituted piperidine analogs and their use as subtype selective nmda receptor antagonists
WO1998015550A1 (en) * 1996-10-04 1998-04-16 Novo Nordisk A/S N-substituted azaheterocyclic compounds
DE19643790A1 (de) 1996-10-30 1998-05-07 Merck Patent Gmbh Benzoxazol-Derivat

Also Published As

Publication number Publication date
TR200003888T2 (tr) 2001-06-21
EP1089735B1 (en) 2005-06-08
OA11570A (en) 2004-07-01
IL138949A0 (en) 2001-11-25
AU4830399A (en) 2000-01-17
EA200100058A1 (ru) 2001-08-27
US6284774B1 (en) 2001-09-04
JP2002519322A (ja) 2002-07-02
ES2244201T3 (es) 2005-12-01
WO2000000197A1 (en) 2000-01-06
NO20006482D0 (no) 2000-12-19
DE69925730T2 (de) 2006-03-23
BG105082A (en) 2001-09-28
DE69925730D1 (de) 2005-07-14
ID28005A (id) 2001-05-03
EP1089735A1 (en) 2001-04-11
EP1089735A4 (en) 2002-12-18
HUP0102471A2 (hu) 2002-05-29
NZ508808A (en) 2002-12-20
PL345024A1 (en) 2001-11-19
AU769650B2 (en) 2004-01-29
ZA200005848B (en) 2001-12-18
SK19512000A3 (sk) 2001-08-06
CA2327888A1 (en) 2000-01-06
IS5667A (is) 2000-10-16
BR9911575A (pt) 2001-03-20
AP2000001949A0 (en) 2000-12-31
CN1304307A (zh) 2001-07-18
NO20006482L (no) 2000-12-19
ATE297207T1 (de) 2005-06-15
PE20000728A1 (es) 2000-08-21
KR20010053170A (ko) 2001-06-25

Similar Documents

Publication Publication Date Title
EE200000778A (et) 4-bensüülpiperidiinalküülsulfoksiidi heterotsüklid ja nende kasutamine NMDA retseptori alaliikide suhtes selektiivsete antagonistidena
PT1009732E (pt) 1-amino-alquilciclo-hexanos antagonistas do receptor nmda
FI20002103A (fi) Amidijohdannaisia ja nosiseptiiniantagonisteja
PT1131291E (pt) Antagonistas iii do receptor 4-aroil-piperidin-ccr-3
IS5706A (is) Adenosín A3 viðtakastillar
ID27212A (id) Senyawa-senyawa 1-piperidil benzimidazol tersubstitusi-2 atau agonis-agonis reseptor orl-1
DE69812096T2 (de) Neuropeptid y rezeptorantagonisten
EE200400025A (et) 5-HT retseptori ligandid ja nende kasutamine
PT1042301E (pt) Novos derivados de acilguanidina como inibidores da absorcao ossea e como antagonistas do receptor da vitronectina
DE60112322D1 (de) Aminothiazole und deren verwendung als adenosinrezeptorantagonisten
ID19253A (id) Bahan antagonis reseptor vitronektin, pembuatannya dan penggunaannya
DE69734833D1 (de) Vitronektin rezeptor antagonisten
EE200300244A (et) 3-aroüülindooli derivaadid ja nende kasutamine CB2-retseptorite agonistidena
FI970310A (fi) 4-indolijohdannaiset serotoniinin vaikuttaja- ja vastavaikuttaja-aineina
DE69728392D1 (de) Indolderivate verwendbar als endothelinrezeptorantagonisten
PT1157005E (pt) Derivados de 3-fenilpirina e a sua utilizacao como antagonistas do receptor nk-1
IL152700A0 (en) Substituted 1-aminoalkyl-lactams and their use as muscarinc receptor antagonists
PT1036072E (pt) Antagonistas de receptores de trombina
DE60114413D1 (de) Substituierte 1-aminoalkyl-lactame und deren verwendung als muscarinrezeptor-antagonisten
NO950606D0 (no) Adhesjonsreseptor-antagonister
ID22916A (id) Turunan-turunan ergolin dan penggunaannya sebagai antagonis reseptor somatostatin
DE69903961T2 (de) Muscarinagonisten und antagonisten
EE200200667A (et) Bitsüklilised tsükloheksüülamiinid ja nende kasutamine NMDA retseptori antagonistidena
ID19245A (id) Antagonis reseptor vitronektin, pembuatannya dan pemakaiannya
ID26223A (id) Antagonis reseptor vitronektin